Key result
Thyroid disease in AF linked to higher anticoagulant use despite similar stroke and bleeding risks.
Why the study?
Although thyroid disease is an established risk factor for AF, few studies have examined its impact on AF treatment.
Does the presence of thyroid disease affect clinical characteristics and treatment patterns in patients with atrial fibrillation?
Observational (n=2,000)
Yes
Does the presence of thyroid disease affect clinical characteristics and treatment patterns in patients with atrial fibrillation?
In a Middle Eastern registry of AF patients, comorbid thyroid disease was present in 10.5% and was associated with a higher burden of comorbidities and increased anticoagulant use.
Answers are grounded in this paper and cite their sources.
Higher anticoagulant use in thyroid-comorbid AF warrants caution in interpretation; leaves open need for adjusted prospective studies on decision-making.
Thyroid disease is a well-established risk factor for atrial fibrillation (AF). However, only a handful of studies examined its impact on treatment. This study aims to report the prevalence rate of thyroid disease in patients with AF and to demonstrate the effect of thyroid disease on AF treatment. We retrospectively analyzed the Jordanian Atrial Fibrillation Study (JoFib). Among Jordan and Palestine, patients with AF were evaluated for their sociodemographic, clinical, and pharmacological characteristics. A total of 2000 patients with AF (53.3% males, mean age 67.6 ± 13.1 years) were enrolled in the JoFib registry from May 2019 to November 2020. Thyroid disease was present in 210 (10.5%) patients. Hypertension, diabetes mellitus, and dyslipidemia were the most common comorbidities among patients with thyroid history (75.2%, 51.0%, and 45.7%, respectively). Diabetes mellitus (p = .04), pulmonary hypertension (p = .01), and chronic kidney disease (p = .01) were significantly higher in this particular subgroup. Patients with thyroid disease demonstrated significantly higher usage of anticoagulants (p = .02). Despite having similar stroke and bleeding risks, patients with thyroid disease demonstrated meaningful differences in their baseline characteristics. Prospective studies are required to assess the influence of thyroid hormone fluctuations on the progression of AF.
No takes yet. Share an insight, caveat, or question.
Al-Makhamreh et al. (2022) conducted an observational in Atrial fibrillation (n=2,000). Thyroid disease vs. No thyroid disease was evaluated on Usage of anticoagulants (p=.02). In patients with atrial fibrillation, comorbid thyroid disease was associated with higher usage of anticoagulants despite similar stroke and bleeding risks.
Synapse has enriched 10 related papers. Consider them for comparative context: